Methods for using a phosphodiesterase in pharmaceutical screenin

Details Methods for using a phosphodiesterase in pharmaceutical screenin Methods for using a phosphodiesterase in pharmaceutical screenin

1998-12-19

2000-12-05

Gitomer, Ralph

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving oxidoreductase

435 13, 435 19, 435184, C12Q 126

Patent

active

061565288

ABSTRACT:
This invention provides a method to identify compounds potentially useful for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.

REFERENCES:
patent: 3031450 (1962-04-01), Fischer et al.
patent: 3161654 (1964-12-01), Shen
patent: 3322755 (1967-05-01), Roch et al.
patent: 3517005 (1970-06-01), Cronin et al.
patent: 3594480 (1971-07-01), Cronin et al.
patent: 3647858 (1972-03-01), Hinkley et al.
patent: 3654349 (1972-04-01), Shen et al.
patent: 3780040 (1973-12-01), Schnettler et al.
patent: 3812127 (1974-05-01), Cronin et al.
patent: 3819631 (1974-06-01), Broughton et al.
patent: 3865840 (1975-02-01), Carson
patent: 3920636 (1975-11-01), Takahasi et al.
patent: 4001237 (1977-01-01), Partyka et al.
patent: 4001238 (1977-01-01), Partyka et al.
patent: 4039544 (1977-08-01), Broughton et al.
patent: 4060615 (1977-11-01), Matier et al.
patent: 4076711 (1978-02-01), Ganguly et al.
patent: 4079057 (1978-03-01), Juby et al.
patent: 4098788 (1978-07-01), Crenshaw et al.
patent: 4101548 (1978-07-01), Crenshaw et al.
patent: 4102885 (1978-07-01), Crenshaw et al.
patent: 4138561 (1979-02-01), Crenshaw et al.
patent: 4146718 (1979-03-01), Jenks et al.
patent: 4161595 (1979-07-01), Kaplan et al.
patent: 4171363 (1979-10-01), Crenshaw et al.
patent: 4208521 (1980-06-01), Crenshaw et al.
patent: 4209623 (1980-06-01), Juby
patent: 4423075 (1983-12-01), Dvornik et al.
patent: 4457927 (1984-07-01), Biere et al.
patent: 4460590 (1984-07-01), Moller
patent: 4460591 (1984-07-01), DeGraw et al.
patent: 4837239 (1989-06-01), Benjamin et al.
patent: 4880810 (1989-11-01), Lowe, III et al.
patent: 4885301 (1989-12-01), Coates
patent: 4923874 (1990-05-01), McMahon et al.
patent: 4971972 (1990-11-01), Doll et al.
patent: 5073559 (1991-12-01), Coates
patent: 5091431 (1992-02-01), Tulshian et al.
patent: 5147875 (1992-09-01), Coates et al.
patent: 5175151 (1992-12-01), Afonso et al.
patent: 5223501 (1993-06-01), Chakravarty et al.
patent: 5239083 (1993-08-01), Kumazawa et al.
patent: 5250535 (1993-10-01), Verheyden et al.
patent: 5254571 (1993-10-01), Coates et al.
patent: 5358952 (1994-10-01), Moschel et al.
patent: 5376683 (1994-12-01), Klar et al.
patent: 5393755 (1995-02-01), Neustadt et al.
patent: 5401774 (1995-03-01), Pamukcu et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 5464861 (1995-11-01), Dobrusin et al.
patent: 5488055 (1996-01-01), Kumar et al.
patent: 5614530 (1997-03-01), Kumar et al.
patent: 5614627 (1997-03-01), Takase et al.
patent: 5674876 (1997-10-01), Gilbert et al.
patent: 5696159 (1997-12-01), Gross et al.
patent: 5728563 (1998-03-01), Tanaka
patent: 5731167 (1998-03-01), Stracke et al.
patent: 5756818 (1998-05-01), Buchmann et al.
patent: 5798246 (1998-08-01), Au-Young et al.
patent: 5798373 (1998-08-01), Warrellow
patent: 5849770 (1998-12-01), Head et al.
patent: 5852035 (1998-12-01), Pamukcu et al.
patent: 5858694 (1999-01-01), Piazza et al.
patent: 5869519 (1999-09-01), Karanewsky et al.
patent: 5874440 (1999-02-01), Pamukcu et al.
patent: 5891896 (1999-04-01), Warrellow et al.
patent: 5922595 (1999-07-01), Fisher et al.
patent: 5932423 (1999-08-01), Au-Young et al.
patent: 5932465 (1999-08-01), Loughney
patent: 5942520 (1999-08-01), Pamukcu et al.
patent: 5948779 (1999-09-01), Sperl et al.
patent: 6015677 (2000-01-01), Beavo et al.
Earnest D. Piroxicam and Other cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention. J of Cellular Biochemistry Supplement 161:156-166, 1992.
Jiang X. Inhibition of Calmodulin-Dependent Phosphodiesterase Induces Apoptosis in Human Leukemic Cells. Proc Natl Acad Sci USA 93:11236-41, Oct. 1996.
Ahlstrom, M.; Lamberg-Allardt, C., Regulation of adenosine 3',5'-cyclic monophosphate (cAMP) accumulation in UMR-106 osteoblastlike cells: role of cAMP-phosphodiesterase and cAMP efflux, Biochem. Pharmacol. (1999), 58(8), 1335-1340.
Ahn, H.S. et al., Effects of Selective Inhibitors on Cyclic Nucleotide Phosphodiesterases of Rabbit Aorta, Biochemical Pharmacology, vol. 38, No. 19, pp. 3331-3339 (1989).
Ahn, Ho-Sam et al., Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity; J. Med. Chem. 1997, 40, pp. 2196-2210.
Altiok N. et al., Bradykinin inhibition of cyclic AMP accumulation in D384 astrocytoma cells. Evidence against a role of cyclic GMP, Neurochem Int. 1992 Sep.; 21(2):209-13.
Anderson, Thomas L. G. et al., Interactions between isoprenaline, sodium nitroprusside, and isozyme-selective phosphodiesterase inhibitors on ADP-induced aggretation and cyclic Nucleotide levels in human platelets (Abstract Only), J. Cardiovasc. Pharmacol. 18(2) pp. 237-242 (1991).
Antonenko S.G. et al., [The role of the components of the cyclic nucleotide system in N-nitrosodiethylamine-induced hepatic carcinogenesis in rats] (Article in Russian), Eksp. Onkol. 1990;12(5):18-21.
Badrieh, Y., et al., Chem. Ber., vol. 125, pp. 667-674 (1992).
Barnett, Mary S. et al., Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle (Abstract Only), J. Pharmacol. Exp. Ther., 264(2) pp. 801-812 (1993).
Belousova, A. K. et al., Role of cyclic nucleotides in tumor growth regulation, (Article written in Russian) Vestn. Akad. Med, Nauk SSSR (1980), (6), 86-9.
Beltman, Jerlyn et al., Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains, Mol. Pharmacol. (1995), 47(2), 330-9.
Bergstrand, Hakan et al., Effects of Antiallergic Agents, Compound 48/80, and Some Reference Inhibitors on the Activity of Partially Purified Human Lung Tissue Adenosine Cyclic 3',5'-Monophosphate and Guanosine Cyclic 3',5'-Monophosphate Phosphodiesterases, Molecular Pharmacology, 13, pp. 38-43 (1976).
Biddle, William et al., Antineoplastic Effect of the Pyrimido-Pyrimidine Derivative: RA 233, Pathologie Biologie, Jan., 1984, pp. 9-13.
Bjarnason et al., Gastroenterology, vol. 94, No. 4, pp. 1070-1074 (1988).
Blaya, C. et al., Effect of the protein kinase inhibitors, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 and N-(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide H-8 on Lewis lung carcinoma tumor progression, European Journal of Pharmacology, 354, pp. 99-104 (1998).
Brogden, R.N. et al., Drugs, vol. 16, pp. 97-114 (1978).
Broughton, B.J. et al., Antiallergic Activity of 2-Phenyl-8-azapruin-6-ones, Journal of Medicinal Chemistry, vol. 18, No. 11, pp. 1117-1118 (1975).
Butt, Elke et al., Characterization of cyclic nucleotide phosphodiesterases with cyclic MAP analogs: topology of the catalytic sites and comparison with other cyclic AMP-binding proteins, Mol. Pharmacol. (1995), 47(2), 340-7.
Carter et al., Chemotherapy of Cancer, 2.sup.nd Ed., John Wiley & Sons, NY, NY, 1981, pp. 362-365.
Chang, W. et al., Sulindac Sulfone Modulates the Expression and Cellular Localization of b-Catenin in Human Colon Carcinoma Cells, Digestive Disease Week, Apr. 1, 1999.
Clarke, W.R. et al., The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance (Abstract Only), Pulm. Pharmacol., 7(2), pp. 81-89, (1994).
Cohan, V.L. et al., In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633, J. Pharmacol. Exp. Ther. (1996), 278(3), 1356-1361.
Cohen L.A. et al., Cyclic nucleotide phosphodiesterase activity in normal and neoplastic rat mammary cells grown in monolayer culture, Cancer Res. 1976 Jun.;36(6):2007-12.
Cote, Mylene, et al., Comparative involvement of cyclic nucleotide phosphodiesterases and adenylyl cyclase on adrenocorticotropin-induced increase of cyclic adenosine monophosphate in rat and human

Affiliated with

Also associated with

Rating

Methods for using a phosphodiesterase in pharmaceutical screenin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for using a phosphodiesterase in pharmaceutical screenin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using a phosphodiesterase in pharmaceutical screenin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-960367